NEP-GROUP
16.2.2024 09:16:29 CET | Business Wire | Press release
NEP Group, the leading worldwide media technology partner for live sports and entertainment, announced today that Lise Heidal has been appointed President, NEP Europe for NEP Broadcast Services, effective 1 April. Based in Norway, Heidal will set the strategy, priorities and focus areas for nine countries in Northern, Central and Southern Europe, as well as in the UK and Ireland, to lead the future planning of NEP’s broadcast services businesses.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240216806377/en/
Industry veteran Lise Heidal has been appointed President, NEP Europe for NEP Broadcast Services. She will set the strategy, priorities and focus areas for all countries in Northern, Central and Southern Europe, as well as in the UK and Ireland, to lead the future planning of NEP’s broadcast services businesses. (Photo: Business Wire)
With over 25 years of multifaceted experience in the media, telecom, and consulting industries, Heidal stands out as a pragmatic leader committed to driving operational excellence, business transformation and strategic innovation. Known as someone committed to building great teams with a genuine interest in the people she works with, Heidal’s approach combines strategic vision and operational expertise, whilst fostering a culture of accountability. Most recently she served 2,5 years as the VP of Production at TV 2, the largest commercial broadcaster in Norway. Prior to that, she served as Managing Director of NEP Norway and led several global NEP initiatives that achieved continuous development and profitable growth from 2010 to 2021.
As part of the new European leadership team, Christer Pålsson has been named Chief Commercial Officer for Europe, reporting into Heidal. As CCO, Pålsson will be responsible for all commercial and sales activities across the region and work closely with NEP’s global sales team to align strategy and execution, including for major events worldwide. He brings with him extensive experience in business leadership, sales, client service, partnerships and operations for NEP in the Nordics, Central and Southern Europe. Prior to joining NEP, Pålsson was Head of International Sales for Mediatec Broadcasting company, which became a part of NEP in 2015.
To support this transition NEP is also pleased to announce that Jose (Tex) Teixeira will join NEP on 4 April initially as President for NEP Nordics, Central & Southern Europe. Teixeira brings with him over 30 years of sport broadcast experience delivering world-class live productions in Africa and New Zealand. A creative, loyal and energetic individual with a can-do spirit, he has specialised in content strategy and acquisition, programming and production, leading large teams, building dynamic environments and managing strategic relationships with rights holders, federations and suppliers across multiple territories throughout his career. He most recently served as Chief Content Officer for SuperSport and as their Interim CEO in 2023.
Rounding out the European senior leadership team, Arjan van Westerloo and Steve Jenkins will continue in their current roles as President, NEP The Netherlands, and President, NEP UK & Ireland, respectively.
Mike Werteen, Global President of NEP Broadcast Services, said: “Combining our UK and European businesses under a single, dynamic and experienced leadership team is an exciting step forward. Having such a powerful group in place enables us to achieve our vision to be the leading global media services provider in live sports and entertainment. Under Lise’s direction, supported by the foundations that all European and UK team members have put into place, I’m confident we will be able to harness all of the talent, synergies, sales and employee career opportunities across these important markets.”
Lise Heidal said: "I am deeply honored to accept the position as lead of the NEP Broadcast Services European organization. It is a privilege to have the opportunity to work with a team of such dedicated and talented individuals. I am fully committed to enhancing our collaborative efforts across Europe, to serving our clients, and to continue building on our shared successes."
While continuing to manage the day-to-day business, the first priority for the European leadership team will be to drive increased collaboration and process improvements for the region as part of the company’s 2024 goals and longer-term plans.
For more information about NEP, visit www.nepgroup.com.
About NEP
You have a vision. We see it, too. With a worldwide network of experts and cutting-edge technology, our unique Global Production Ecosystem empowers content creators and rights holders to tell stories in breakthrough ways. We're built on 35 years of trusted experience across broadcast, live event, and virtual production to deliver the solutions you need—anytime, anywhere.
Headquartered in the United States, NEP has operations in 25 countries with over 5,000 employees. Together, we have supported productions in over 100 countries on all seven continents, and we’re still growing. Learn how we help our clients bring content to life at nepgroup.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240216806377/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom